相关实验视频
Updated: Feb 28, 2026

08:50
Predictive Immune Modeling of Solid Tumors
Published on: February 25, 2020
7.6K
瘤突变负担决定了癌症免疫治疗中的成功和耐药性
1ISEM, Université de Montpellier, CNRS, Montpellier, France.
Journal of theoretical biology
|February 26, 2026
概括
癌症突变会影响免疫治疗的成功. 一个新的模型显示了瘤如何通过无声克隆或免疫逃避来发展抗药性,从而限制了许多患者的治疗效果.
科学领域:
- 进化生物学是进化的生物学.
- 癌症免疫学 癌症免疫学
- 计算瘤学是一种计算瘤学.
背景情况:
- 免疫检查点封锁已经彻底改变了癌症治疗,但显示出有限的持久反应.
- 瘤突变负担 (TMB) 对免疫治疗结果至关重要,但它的作用是复杂的.
- 瘤可以通过免疫逃避或新抗原编辑来发展抵抗力.
研究的目的:
- 为了建模瘤原和免疫原突变的生态进化动态.
- 了解瘤突变负担如何影响癌细胞复制和免疫识别.
- 确定对癌症免疫疗法的先天性和获得性耐药性的机制.
主要方法:
- 开发了癌细胞复制的最小生态进化模型.
- 分析了瘤原和免疫原突变之间的权衡.
- 在免疫压力下模拟瘤进化.
主要成果:
- 鉴定出一种进化的双模式模式,其中静默和突变活跃的瘤并存.
- 证明了高的TMB可以庇护先前存在的耐药克隆.
- 表明免疫压力驱动免疫编辑和选择降低抗原性.
结论:
- 瘤突变负担在免疫疗法反应和耐药性方面发挥着双重作用.
- 生态进化动力学解释了关键的抗性机制,如先前存在的抗性和免疫编辑.
- 了解这些进化策略对于提高癌症免疫疗法疗效至关重要.
更多相关视频
09:32Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells
Published on: February 8, 2018
15.6K
07:47Author Spotlight: Unveiling Transmembrane Protein Family-Related Markers in Gastric Cancer and Implications for Targeted Therapies
Published on: September 15, 2023
2.3K
相关概念视频
Tumor Immunotherapy
2.1K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.1K
The Tumor Microenvironment
8.0K
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
8.0K
Mismatch Repair
6.8K
Organisms are capable of detecting and fixing nucleotide mismatches that occur during DNA replication. This sophisticated process requires identifying the new strand and replacing the erroneous bases with correct nucleotides. Mismatch repair is coordinated by many proteins in both prokaryotes and eukaryotes.
The Mutator Protein Family Plays a Key Role in DNA Mismatch Repair
The human genome has more than 3 billion base pairs of DNA per cell. Prior to cell division, that vast amount of genetic...
The Mutator Protein Family Plays a Key Role in DNA Mismatch Repair
The human genome has more than 3 billion base pairs of DNA per cell. Prior to cell division, that vast amount of genetic...
6.8K
Cancer-Critical Genes II: Tumor Suppressor Genes
9.9K
Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
9.9K
Treatment Resistant Cancers
3.8K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.8K
mTOR Signaling and Cancer Progression
4.9K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
4.9K